| Website | ascentrx.com |
| Category | BioTech |
| Phone | 617-715-1999 |
| info@ascentrx.com | |
| Employees |
| TOTAL | $8M |
| FUNDING TOTAL | $8M |
| Series A, 11/07 HealthCare Ventures Novartis Bioventures TVM Capital | $8M |
Ascent Therapeutics is pioneering a new class of drugs called pepducins. Pepducins are a breakthrough approach to targeting G-protein coupled receptors (GPCRs) on the inside surface of the cell membrane, dramatically expanding the GPCR frontier. GPCRs are critically involved in a wide variety of serious illnesses, including inflammation, cancer, metabolic CNS disorders and cardiovascular disease. Pepducin technology represents an exciting new area of research directed towards a well-validated class of drug targets.
